| avelumab based treatment | durvalumab based treatment | nivolumab based treatment | pembrolizumab based treatment |
| avelumab alone | durvalumab alone | nivolumab alone | pembrolizumab alone | pembrolizumab plus 5FU plus platin |
Comparator:
vs placebo; vs cetuximab plus platin plus 5FU; vs Standard of Care (SoC);
Risk of bias:
low;
some concerns;
high;
NA;